371 related articles for article (PubMed ID: 30702996)
1. Lipid-Lowering Agents.
Hegele RA; Tsimikas S
Circ Res; 2019 Feb; 124(3):386-404. PubMed ID: 30702996
[TBL] [Abstract][Full Text] [Related]
2. A new dawn for managing dyslipidemias: The era of rna-based therapies.
Macchi C; Sirtori CR; Corsini A; Santos RD; Watts GF; Ruscica M
Pharmacol Res; 2019 Dec; 150():104413. PubMed ID: 31449975
[TBL] [Abstract][Full Text] [Related]
3. New Therapeutic Approaches for Familial Hypercholesterolemia.
Ajufo E; Rader DJ
Annu Rev Med; 2018 Jan; 69():113-131. PubMed ID: 29414257
[TBL] [Abstract][Full Text] [Related]
4. Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention.
Michaeli DT; Michaeli JC; Albers S; Boch T; Michaeli T
Am J Cardiovasc Drugs; 2023 Sep; 23(5):477-495. PubMed ID: 37486464
[TBL] [Abstract][Full Text] [Related]
5. Biotechnology Approaches for the Treatment of Dyslipidemia.
Parolini C
Cardiovasc Drugs Ther; 2021 Feb; 35(1):167-183. PubMed ID: 32519066
[TBL] [Abstract][Full Text] [Related]
6. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
Reiner Z
Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
[TBL] [Abstract][Full Text] [Related]
7. New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs.
Norata GD; Ballantyne CM; Catapano AL
Eur Heart J; 2013 Jun; 34(24):1783-9. PubMed ID: 23509227
[TBL] [Abstract][Full Text] [Related]
8. Role of Bempedoic Acid in Dyslipidemia Management.
Kelly MS; Sulaica EM; Beavers CJ
J Cardiovasc Pharmacol; 2020 Oct; 76(4):376-388. PubMed ID: 32732494
[TBL] [Abstract][Full Text] [Related]
9. Effects of ezetimibe on remnant-like particle cholesterol, lipoprotein (a), and oxidized low-density lipoprotein in patients with dyslipidemia.
Nozue T; Michishita I; Mizuguchi I
J Atheroscler Thromb; 2010 Feb; 17(1):37-44. PubMed ID: 20075599
[TBL] [Abstract][Full Text] [Related]
10. [HDL, or non-HDL: that is the question. Possibilities of pharmacological treatment in residual dyslipidaemia].
Bajnok L
Orv Hetil; 2014 Jan; 155(2):62-8. PubMed ID: 24389322
[TBL] [Abstract][Full Text] [Related]
11. Niacin and lipoprotein(a): facts, uncertainties, and clinical considerations.
Scanu AM; Bamba R
Am J Cardiol; 2008 Apr; 101(8A):44B-47B. PubMed ID: 18375241
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive lipid management versus aggressive low-density lipoprotein lowering to reduce cardiovascular risk.
Knopp RH; Paramsothy P; Atkinson B; Dowdy A
Am J Cardiol; 2008 Apr; 101(8A):48B-57B. PubMed ID: 18375242
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of low high-density lipoprotein cholesterol and hypertriglyceridaemia in patients treated with hypolipidaemic drugs.
Laforest L; Souchet T; Moulin P; Ritleng C; Desamericq G; Le Jeunne P; Schwalm MS; Van Ganse E
Arch Cardiovasc Dis; 2009 Jan; 102(1):43-50. PubMed ID: 19233108
[TBL] [Abstract][Full Text] [Related]
14. Can Lp(a) Lowering Against Background Statin Therapy Really Reduce Cardiovascular Risk?
Reiner Ž
Curr Atheroscler Rep; 2019 Mar; 21(4):14. PubMed ID: 30847681
[TBL] [Abstract][Full Text] [Related]
15. The Role of Antisense Therapies Targeting Lipoprotein(a).
Plakogiannis R; Sorbera M; Fischetti B; Chen M
J Cardiovasc Pharmacol; 2021 Jul; 78(1):e5-e11. PubMed ID: 34232223
[TBL] [Abstract][Full Text] [Related]
16. Poststatin Lipid Therapeutics: A Review.
Jia X; Lorenz P; Ballantyne CM
Methodist Debakey Cardiovasc J; 2019; 15(1):32-38. PubMed ID: 31049147
[TBL] [Abstract][Full Text] [Related]
17. A Review of the Efficacy and Tolerability of Bempedoic Acid in the Treatment of Hypercholesterolemia.
Niman S; Rana K; Reid J; Sheikh-Ali M; Lewis T; Choksi RR; Goldfaden RF
Am J Cardiovasc Drugs; 2020 Dec; 20(6):535-548. PubMed ID: 32166726
[TBL] [Abstract][Full Text] [Related]
18. Lipids and Cerebrovascular Disease: Research and Practice.
Yaghi S; Elkind MS
Stroke; 2015 Nov; 46(11):3322-8. PubMed ID: 26451029
[No Abstract] [Full Text] [Related]
19. Practical management of dyslipidemia with elevated lipoprotein(a).
Riche DM; East HE; Priest HM
J Am Pharm Assoc (2003); 2008; 48(6):803-7. PubMed ID: 19019811
[TBL] [Abstract][Full Text] [Related]
20. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial.
Thomas GS; Cromwell WC; Ali S; Chin W; Flaim JD; Davidson M
J Am Coll Cardiol; 2013 Dec; 62(23):2178-84. PubMed ID: 24013058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
